[1] Wang Xin, Chen Guangwei, Yang Yang, et al. Fuzheng Anticancer Formula and Chaishao Liujunzi Decoction Combined with Bevacizumab + FOLFOX Regimen in the Treatment of Metastatic Colorectal Cancer [J]. Modern Traditional Chinese Medicine, 2020, (06): 70-76. [doi: 10.13424/j.cnki.mtcm.2020.06.017]
Fuzheng Anticancer Formula and Chaishao Liujunzi Decoction Combined with Bevacizumab + FOLFOX Regimen in the Treatment of Metastatic Colorectal Cancer
- Article number:
- 1672-0571(2020)06-0070-07
- Keywords:
- Fuzheng Anticancer Decoction; Chaishao Liujunzi Decoction; Bevacizumab; FOLFOX Regimen; liver stagnation and spleen deficiency; Metastatic Colorectal Cancer
- ZTFLH:
- R273
- Code:
- A
- Abstract:
- Objective To observe the clinical effect of Fuzheng Anticancer Decoction and Chaishao Liujunzi Decoction ( ingrediants include ginseng, atractylodes rhizome, tuckahoe, orange peel, pinellia ternata ( ginger) , liquorice root, bupleurum root, white peony root, rattan hook) combined with bevacizumab + FOLFOX regimen in the treatment of metastatic colorectal cancer. Methods A retrospective analysis of 53 cases of mCRC patients diagnosed as liver stagnation and spleen deficiency according to TCM syndrome differentiation ranging from July 2016 to December 2018. According to the previous treatment plan, they were divided into control group with 26 cases and given bevacizumab + FOLFOX regimen chemotherapy; 27 cases in the treatment group were treated with bevacizumab + FOLFOX regimen chemotherapy plus oral Fuzheng Anticancer formula and Chaishao Liujunzi Decoction. The objective response rate ( ORR) , disease control rate ( DCR) , progression - free survival ( PFS) , adverse reaction rate and clinical symptom improvement rate of the two groups were compared. Results The ORR and DCR of the treatment group were significantly higher than those of the control group, and the difference was statistically significant ( P < 0. 05) . The median progression - free survival time ( mPFS) of patients in the treatment group was 12. 60 ±0. 74 months ( 95% CI: 11. 15 -14. 05 months) , and the median progression - free survival time ( mPFS) of patients in the control group was 10. 40 ±0. 70 months ( 95% CI: 9. 03 -11. 78 months) , the difference was statistically significant ( χ2 =6. 63, P =0. 01) . During the course of treatment, the incidence of toxic reactions such as nausea, vomiting, leukopenia, thrombocytopenia, pigmentation, and sensory neurotoxicity in the treatment group were significantly lower than those in the control group, and the difference was statistically significant ( P <0. 05) . In addition, the treatment group was better than the control group in improving the clinical symptoms of mCRC patients with liver depression and spleen deficiency , such as anorexia, discomfort in stomach, abdominal distension and uncomfortable stools, and the difference was statistically significant ( P <0. 05) . Conclusion Fuzheng Anticancer Formula combined with Chaishao Liujunzi Decoction combined with bevacizumab + FOLFOX regimen in the treatment of mCRC patients with liver stagnation and spleen deficiency can significantly improve the patients’ ORR, DCR,PFS, reducing the side effects of chemotherapy and improving the quality of patients’ life .
References:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA: a Cancer Journal for Clinicians, 2017,67(1): 7-30.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J] . CA: ACancer Journal for Clinicians,2018,68(6):394-424.
[3] Shafiee M, Aleyasin SA, Vasei M, et al. Down – regulatory effects of miR-211 on long non-coding RNA SOX2OT and SOX2 genes in esophageal squamous cell carcinoma[J] . Cell,2016,17(4):593-600.
[4]余伟.转移性结直肠癌一线全身治疗方案疗效评价的网状meta分析[D].重庆:重庆医科大学,2019.
[5] Messersmith, Wells A.Systemic Management of Colorectal Cancer [J]. Journal of the National Comprehensive Cancer Network Jnccn,2017,15(5S):699.
[6]谢永铮,任学群.贝伐珠单抗联合FOLFOX治疗晚期转移性结直肠癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(22):2208-2210.
[7]陈光伟,殷群,吕予.恶性肿瘤转移中医防治浅析[J].陕西中医,2011,32(5):638-639.
[8]]杨越,刘宁宁,张程程,等.大肠癌转移的中医病机探讨[J].中华中医药学刊,2018,36(9):2214-2216.
[9]刘平,李雁,徐静,等.扶正祛邪治则在大肠癌治疗中的应用[J].现代中西医结合杂志,2019,28(15):1692-1696.
[10] Hashiguchi Y, Muro k, Saito Y, etal. Japanese Societg for Cancer of the Colon and Retecturm (JSCCR) guidelines 2019 for the treatment for the treatment of colorectal cancer[J]. Int J Chin Oncol ,2020,25(1):1-42.
[11]马聪明.疏木扶土方治疗结直肠癌术后肝郁脾虚型肠郁的临床研究[D].昆明:云南中医药大学,2019.
[12]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:362.
[13] Morse B, Jeong D, Ihnat G, et al. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1. 1non-target lesion assessment[J]. Abdominal Radiology,2019,44(2):766-774.
[14] Price T, Shen L, Ma B, et al. Phase II APEC trial: The impact of primary tumor side on outcomes of first - linecetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer[J]. Asia–Pacific Journal of Clinical Oncology,2019,15(4):225-230.
[15] Elferink MAG, Jong KP, Klaase JM, et al. Metachronous metastases from colorectal cancer: a population – based study in North-East Netherlands[J]. International Journal of Colorectal Disease,2015,30(2):205-212.
[16]梁芳,袁旭,于宏杰,等.基于“虚”本质的大肠癌辨证论治方法探索[J].辽宁中医杂志,2018,45(4):722-725.
[17]史碧霄,曹云,李?.归芍六君子汤加减辅助化疗治疗大肠癌肝转移25例临床研究[J].江苏中医药,2018,50(12):36-38.
[18]谭硕果,梁永艺.半夏泻心汤联合mFOLFOX6方案治疗晚期结肠癌[J].深圳中西医结合杂志,2019,29(22):25-26.
[19]王方杰.不同时机中医补益法协同化疗抗结肠癌的有效性分析[J].中医临床研究,2014,6(8):91-92.
[20] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. The New England Journal of Medicine,2004,350(23):2335-2342.
[21]秦叔逵,邓艳红,毕锋,等.贝伐珠单抗联合含氟尿嘧啶类化疗方案治疗晚期转移性结直肠癌的前瞻性?非干预性?全国多中心临床研究(REACT)[J].临床肿瘤学杂志,2016,21(10):865-873.
[22]孙瑞华,蔡新生.中医药对大肠癌的精准治疗及研究进展[J].陕西中医,2019,40(11):1653-1656.
Memo
基金项目:陕西省科技厅重点研发计划一般项目(2018SF-309);咸阳市科学技术局科技成果推广计划项目(2018KT-23)
通讯作者:杨洋,主治医师?E-mail:doctoryang1985@163.com